Nu-3 Gel for Infected Diabetic Foot Ulcers
Phase 2
Not yet recruiting
- Conditions
- Diabetic Foot Infection
- Interventions
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Lakewood-Amedex Inc
- Target Recruit Count
- 60
- Registration Number
- NCT06020235
Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer
Phase 2
Terminated
- Conditions
- Chronic Diabetic Foot Ulcers
- Interventions
- Drug: 5% Bisphosphocin Topical GelDrug: Placebo Topical GelDrug: 10% Bisphosphocin Topical Gel
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Lakewood-Amedex Inc
- Target Recruit Count
- 3
- Registration Number
- NCT05276401
- Locations
- ๐บ๐ธ
NEA Baptist Clinic, Jonesboro, Arkansas, United States
๐บ๐ธLimb Preservation Platform, Inc., Fresno, California, United States
๐บ๐ธDoctors Research Network, South Miami, Florida, United States
Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus
Phase 1
Completed
- Conditions
- Diabetic Foot Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-04-14
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Lakewood-Amedex Inc
- Target Recruit Count
- 31
- Registration Number
- NCT02737722
- Locations
- ๐บ๐ธ
Clinical Research Solutions, Franklin, Tennessee, United States
๐บ๐ธCenter for Clinical Research, Inc., San Francisco, California, United States
๐บ๐ธJourney Research, Inc., Oldsmar, Florida, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath